Skip to main content
. 2020 Mar 17;25(6):1370. doi: 10.3390/molecules25061370

Figure 7.

Figure 7

Antagonist action of co-administered naloxone methiodide (NAL-M) on the antinociceptive effect of 14-OMeC6SU (A) and C6SU (B) in CFA-induced inflammatory pain 30 min after the injection of the compounds. Figures indicate the paw pressure threshold in g-s in the presence of 14-OMeC6SU, C6SU and NAL-M, and in the presence of NAL-M co-administered with 14-OMeC6SU or C6SU in the indicated dosages. Data represent means ± S.E.M. (n = 5–11 per group). # significant difference within the inflamed paw compared to vehicle, NAL-M and to 6.1 µmol/kg 14-OMeC6SU + NAL-M in panel A (two-way ANOVA, Tukey’s multiple comparisons test). × significant difference within the inflamed paw compared to the correspondent test compound alone in the appropriate dose (two-way ANOVA, Tukey’s multiple comparisons test). ××/## P < 0.01; ×××/### P < 0.001.